Estramustine phosphate with multiple cytotoxic agents in treatment of advanced prostatic cancer.
Twenty-five patients with histologically proved adenocarcinoma of the prostate were divided into two groups and submitted to combination therapy with estramustine (Estracyt), cyclophosphamide (Cytoxan), 5-fluorouracil, and Cisplatin. Group A consisted of 10 patients newly diagnosed Stage D disease with no prior treatment. Group B consisted of 15 Stage D patients who had become hormonally unresponsive. Group A patients demonstrated an initial 100 per cent response rate including 70 per cent partial objective responses and 30 per cent stabilizations. Group B patients had a 46 per cent response with 39 per cent complete and partial responses and 6 per cent as stabilized. Toxicity was tolerable judged by the NPCP criteria. Both groups of patients are still under study for up to two years to determine if this therapy is superior to other traditional therapies.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D004961:Estramustine / Q000008:administration & dosage*; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage*; D010865:Pilot Projects; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D004961:Estramustine; D003520:Cyclophosphamide; D002945:Cisplatin; D005472:Fluorouracil